ChartRow logo
Data provided bySource: Twelve Data
PEN
$319.11-0.47%
as of close, Nov 17, 2026
☾ AH $319.11 -0.47%
PeersSNNOHIELANMEDPNYTNLY
Share this page

PEN — Penumbra Inc. price, chart and key statistics

Technical analysis2
Overlay lines0
Addendum charts0
Data provided bySource: Twelve Data
What would $1,000 invested in PEN be worth today? →
PEN returns: By year · By month · By week · Trailing

Price data

Price
$319.11
YTD price return
+2.64%
YTD total return
+2.64%
Market cap
12.6B
Enterprise value
12.5B
Shares outstanding
39.4M
52W low
$276.01
52W high
$362.41
From 52W high
-11.95%
From 52W low
+15.62%
52W range
50%$276–$362
Beta
0.70

Volume

Rel volume
0.98×
30D volume
373.1K
30D $ vol
119.8M

Insider trading

Insider net 1W
none
Insider net 1M
none
Insider net 3M
none
Insider net 1Y
−$981K

Form 4 transactions by trade date, as filed; latest on file 2026-04-02.

Fundamentals

Sales (ttm)
1.6B
Sales/share
$39.59
EPS (ttm)
$3.97
FCF (ttm)
200.3M
FCF/share
$5.08
Book value/share
$40.18
Net margin
10.06%
ROE
9.92%
ROA
7.75%
Current ratio
5.89

Growth (CAGR, ttm) · 10Y

Sales
+17.00%+16.17%+17.04%+20.36%
Net income
-4.28%+56.93%+36.15%+23.62%
FCF
+31.26%+61.79%n/an/a
Shares
+0.64%+0.70%+1.08%+2.22%

Per-share growth (CAGR, ttm) · 10Y

EPS
-3.97%+56.79%+34.28%+21.64%
Sales/share
+16.25%+15.36%+15.79%+17.75%
FCF/share
+30.42%+60.66%n/an/a
Book value/share
+15.81%+11.98%+16.79%+17.48%
Price
+14.59%+12.13%+3.67%+17.22%
Total return
+14.59%+12.13%+3.67%+17.22%

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)
80.4×
P/OI (ttm)
66.5×
Fwd P/E
51.8×
P/S (ttm)
8.1×
P/B (mrq)
7.9×
P/FCF (ttm)
62.8×
EV/EBITDA (fy)
59.9×
EV/Sales (ttm)
8.0×
FCF yield (ttm)
1.59%
Buyback yield (realized, 1y)
-0.64%
Shareholder yield (realized, 1y)
-0.64%
Buyback yield (cash, ttm)
0.00%
Shareholder yield (cash, ttm)
0.00%

Vs own 10Y history

P/E
17th
P/OI
7th
P/S
17th
P/B
24th
P/FCF
16th

Bar = where today’s multiple sits in PEN’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).

Performance · price returntotal return · as of 2026-11-17#

Data provided bySource: Twelve Data
1D
-0.47%
5D
-0.73%
1M
-0.55%
3M
-2.46%
YTD
+2.64%
1Y
+14.58%
5Y
+19.74%
1D
-0.47%
5D
-0.73%
1M
-0.55%
3M
-2.46%
YTD
+2.64%
1Y
+14.58%
5Y
+19.74%

Fundamentals#

Revenue

5Y CAGR +20.2%10Y CAGR +22.4%YoY +15.6%
$1.6B TTM$410.1M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Operating income

5Y n/m10Y CAGR +46.4%YoY +3.9%
$189.2M TTM$50.7M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

EPS (diluted)

5Y n/m10Y CAGR +49.7%YoY −8.5%
$3.97 TTM$1.07 Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Free cash flow

5Y n/m10Y n/mYoY −37.2%
$200.3M TTM$26.4M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM

TTM: operating cash flow $261M, capex −$60.8M

Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Q3 2026: operating cash flow $41.5M, capex −$15.1M

Shares (diluted)

5Y +9.9%10Y +176.3%YoY +0.8%
39.5M TTM39.6M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Net income

5Y n/m10Y CAGR +54.0%YoY −7.8%
$157M TTM$42.3M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Full PEN financials →

Penumbra Inc. is a medical device company that designs, develops, manufactures, and markets products for interventional therapies in vascular and neurological care. Its portfolio centers on thrombectomy systems used to remove blood clots, including solutions for peripheral and neurovascular applications, along with access devices, embolization technologies, and neurosurgical tools. The company’s products are used in acute care settings by hospitals and physicians to support treatment of conditions such as stroke, pulmonary embolism, deep vein thrombosis, aneurysms, and other vascular disorders. Penumbra Inc. serves healthcare providers in the United States and international markets, positioning itself as a specialist in minimally invasive devices for complex clot-removal and vascular intervention procedures. Founded in 2004 and headquartered in Alameda, California, Penumbra Inc. focuses on medical technologies that address critical and time-sensitive clinical needs.

Alameda, CA·4,700 employees·Medical Devices·penumbrainc.com·As of Oct 28, 2026

Recent filings#

All filings and insider trades →

ETFs holding PEN#

20 of the 193 ETFs ChartRow carries live hold PEN. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).

FundNameFiled weight
IJHiShares Core S&P Mid-Cap ETF0.3%
MDYSPDR S&P MidCap 400 ETF Trust0.3%
VBKVanguard Small-Cap Growth ETF0.3%
IWPiShares Russell Mid-Cap Growth ETF0.3%
VHTVanguard Health Care ETF0.2%
VXFVanguard Extended Market ETF0.1%
VBVanguard Small-Cap ETF0.1%
IWRiShares Russell Midcap ETF0.1%
TickerName1M1D
LLYEli Lilly and Company+12.61%-1.13%
JNJJohnson & Johnson+9.05%-1.36%
ABBVAbbVie Inc.+2.59%-0.59%
MRKMerck & Co. Inc.-1.77%-0.75%
UNHUnitedHealth Group Incorporated Common Stock (DE)-2.93%-5.42%
NVSNovartis AG+5.65%-0.67%
TMOThermo Fisher Scientific Inc.-0.47%-0.66%
AMGNAmgen Inc.+5.88%-0.95%